Peringatan Keamanan

Organism : Mouse
Test type: LD50 Oral (Reported dose: >6gm/kg)
LD50 Subcutaneous ( >3600mg/kg )
Effects : Behavioral : somnolence ( general depressed activity )
Blood changes in spleen

Organism : Mouse
Test type: LD50
Route: Intraperitoneal
Reported dose: 500 mg/kg

LD50 rat : 1510mg/kg Intraperitoneal
LD50 rat >6gm/kg Oral
LD 50 rat : > 2600mg/kg subcutaneous

Clobetasone

DB13158

small molecule approved

Deskripsi

Clobetasone is a corticosteroid that is often employed topically as a treatment for a variety of conditions such as eczema, psoriasis, various forms of dermatitis, and also for certain ophthalmologic conditions. Topical clobetasone butyrate has shown minimal suppression of the Hypothalamic-pituitary-adrenal axis.

Struktur Molekul 2D

Berat 408.89

Wujud solid

Peta Jejaring Molekuler

Obat Target Gen Interaksi Enzim Transporter Carrier

Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

1. Pendahuluan & Konsep

Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).

2. Sumber Data (Validasi)

Data Obat: Diekstraksi dari elemen drugbank-id dan name pada skema XML DrugBank.
Target Protein: Diambil dari elemen targets/target yang memuat polipeptida sasaran.
Genetik: Disinkronisasi dari sub-elemen gene-name dan varian snp-effects.
Genetik: Jumlah titik node dibatasi pada maksimal 10 (Slice=10) interaksi untuk menghindari tumpukan data.

3. Algoritma Visualisasi

Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.

4. Legenda Visual

Obat Utama (Pusat Analisis)

Target Protein (Mekanisme)

Gen (Faktor Genetik)

Metode ini mendukung analisis Precision Medicine dan evaluasi risiko Drug-Drug Interaction (DDI).

Profil Farmakokinetik

Waktu Paruh (Half-Life) N/A

Volume Distribusi The use of pharmacodynamic endpoints for assessing the systemic exposure of topical corticosteroids is necessary due to the fact that circulating levels are well below the level of detection.

Klirens (Clearance) -

Absorpsi

Absorption is dependent on many drug-related factors including: intrinsic properties of the steroid itself; concentration of the drug (increased concentration generally leads to more drug being absorbed but may plateau at higher concentrations); vehicle used (optimized or augmented vehicles > ointments or gels > creams or lotions); duration of exposure; frequency of application; combination with other products that break down the skin barrier and increase absorption (e.g., salicylic acid, urea). Patient-related factors that influence absorption include: patient age (infants and children absorb topical medications more quickly and to a greater degree than adults, and have a greater total skin surface to body weight ratio; the elderly have thinner skin and absorb drug more readily); disruption of the skin due to inflammation or disease (e.g., absorption increased in atopic dermatitis); total skin area treated; skin site treated (absorption is much greater from thin-skinned areas such as scalp, face, eyelid, axilla, and scrotum than from areas with thicker skin such as forearm, knee, elbow, palm and sole); absorption is increased with increased temperature or humidity of the skin or the environment; occlusion of the treated skin (via plastic wrap, oily vehicles, dressings, tape, diapers, tight-fitting clothing, etc.) can increase absorption up to 10-fold.

Metabolisme

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. They are metabolised, primarily in the liver.

Rute Eliminasi

Clobetasone and its metabolites are excreted in urine.

Interaksi Obat

163 Data

Trastuzumab	The risk or severity of neutropenia can be increased when Trastuzumab is combined with Clobetasone.
Tacrolimus	Tacrolimus may increase the immunosuppressive activities of Clobetasone.
Phenylephrine	The risk or severity of hypertension can be increased when Clobetasone is combined with Phenylephrine.
Aminoglutethimide	The therapeutic efficacy of Clobetasone can be decreased when used in combination with Aminoglutethimide.
Insulin human	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Insulin human.
Insulin lispro	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Insulin lispro.
Insulin glargine	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Insulin glargine.
Insulin pork	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Insulin pork.
Troglitazone	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Troglitazone.
Glimepiride	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Glimepiride.
Sulfisoxazole	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Sulfisoxazole.
Disopyramide	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Disopyramide.
Acarbose	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Acarbose.
Metformin	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Metformin.
Sulfadiazine	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Sulfadiazine.
Rosiglitazone	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Rosiglitazone.
Acetohexamide	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Acetohexamide.
Quinine	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Quinine.
Miglitol	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Miglitol.
Chlorpropamide	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Chlorpropamide.
Nateglinide	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Nateglinide.
Pentamidine	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Pentamidine.
Mifepristone	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Mifepristone.
Tolazamide	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Tolazamide.
Repaglinide	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Repaglinide.
Phenformin	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Phenformin.
Sulfamethoxazole	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Sulfamethoxazole.
Glyburide	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Glyburide.
Glipizide	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Glipizide.
Gliclazide	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Gliclazide.
Tolbutamide	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Tolbutamide.
Pioglitazone	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Pioglitazone.
Bromocriptine	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Bromocriptine.
Gliquidone	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Gliquidone.
Mitiglinide	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Mitiglinide.
Sitagliptin	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Sitagliptin.
Sunitinib	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Sunitinib.
Exenatide	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Exenatide.
Mecasermin	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Mecasermin.
Pramlintide	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Pramlintide.
Glisoxepide	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Glisoxepide.
Insulin aspart	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Insulin aspart.
Insulin detemir	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Insulin detemir.
Insulin glulisine	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Insulin glulisine.
Glymidine	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Glymidine.
AICA ribonucleotide	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with AICA ribonucleotide.
Buformin	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Buformin.
Vildagliptin	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Vildagliptin.
Voglibose	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Voglibose.
NN344	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with NN344.
AMG-222	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with AMG-222.
Bisegliptin	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Bisegliptin.
Alogliptin	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Alogliptin.
Dapagliflozin	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Dapagliflozin.
Saxagliptin	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Saxagliptin.
Liraglutide	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Liraglutide.
Gosogliptin	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Gosogliptin.
Linagliptin	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Linagliptin.
Canagliflozin	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Canagliflozin.
Glibornuride	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Glibornuride.
Benfluorex	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Benfluorex.
Empagliflozin	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Empagliflozin.
Albiglutide	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Albiglutide.
Dulaglutide	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Dulaglutide.
Lobeglitazone	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Lobeglitazone.
Netoglitazone	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Netoglitazone.
Rivoglitazone	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Rivoglitazone.
Ciglitazone	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Ciglitazone.
Lixisenatide	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Lixisenatide.
Insulin beef	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Insulin beef.
Insulin degludec	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Insulin degludec.
Insulin peglispro	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Insulin peglispro.
Insulin tregopil	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Insulin tregopil.
Ipragliflozin	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Ipragliflozin.
Dutogliptin	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Dutogliptin.
Allicin	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Allicin.
Tofogliflozin	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Tofogliflozin.
Ertugliflozin	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Ertugliflozin.
2,4-thiazolidinedione	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with 2,4-thiazolidinedione.
Teneligliptin	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Teneligliptin.
Omarigliptin	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Omarigliptin.
Carmegliptin	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Carmegliptin.
Gemigliptin	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Gemigliptin.
Anagliptin	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Anagliptin.
Evogliptin	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Evogliptin.
Sotagliflozin	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Sotagliflozin.
Balaglitazone	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Balaglitazone.
Remogliflozin etabonate	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Remogliflozin etabonate.
Carbutamide	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Carbutamide.
Guar gum	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Guar gum.
Metahexamide	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Metahexamide.
Semaglutide	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Semaglutide.
Taspoglutide	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Taspoglutide.
Englitazone	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Englitazone.
Tirzepatide	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Tirzepatide.
Gastric inhibitory polypeptide	The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Gastric inhibitory polypeptide.
Isoniazid	The serum concentration of Isoniazid can be decreased when it is combined with Clobetasone.
Cyclosporine	The risk or severity of adverse effects can be increased when Clobetasone is combined with Cyclosporine.
Digoxin	The risk or severity of adverse effects can be increased when Clobetasone is combined with Digoxin.
Acetyldigitoxin	The risk or severity of adverse effects can be increased when Clobetasone is combined with Acetyldigitoxin.

Target Protein

Glucocorticoid receptor NR3C1

Referensi & Sumber

Link

Contoh Produk & Brand

Produk: 4 • International brands: 1

Produk

Eumovate

Ointment • 0.05 % • Topical • Canada • Approved
Eumovate Crm 0.05%

Cream • 0.05 % • Topical • Canada • OTC • Approved
Eumovate Ont 0.05%

Ointment • 0.05 % • Topical • Canada • Approved
Spectro Eczemacare Medicated Cream

Cream • 0.05 % w/w • Topical • Canada • OTC • Approved

International Brands

Eumosone — GlaxoSmithKline

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.